key papersKey paper
Marginal zone lymphomas: ESMO clinical practice guidelines
The ESMO guideline for marginal zone lymphomas sets out the treatment of gastric and non-gastric extranodal, splenic and nodal forms, including antibiotic eradication, low-dose radiotherapy, watch and wait, rituximab-based therapy and BTK inhibitors at relapse.
Overview
Evidence-based guideline covering diagnosis, staging, and first-line and relapsed treatment of extranodal (MALT), splenic and nodal marginal zone lymphomas, including the role of infectious agents (Helicobacter pylori, hepatitis C), involved-site radiotherapy, chemoimmunotherapy and novel agents.
GuidelineChanged practice
Authors
Zucca E, Arcaini L, Buske C, et al.
Published
Annals of Oncology, 2020
What it means
The site-specific and stage-specific approach on the marginal zone lymphoma page follows this guideline.
Caveats
- Randomised evidence is limited for most decisions in these indolent lymphomas.